ICU Medical, Inc. (NASDAQ:ICUI) Receives $127.00 Consensus Target Price from Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has earned a consensus recommendation of “Moderate Buy” from the four analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $127.00.

Several equities research analysts recently commented on the stock. Needham & Company LLC started coverage on shares of ICU Medical in a report on Friday, June 21st. They issued a “hold” rating for the company. Raymond James upgraded shares of ICU Medical from a “market perform” rating to an “outperform” rating and set a $135.00 price target for the company in a research report on Monday, June 17th.

ICU Medical Stock Up 1.1 %

ICUI opened at $118.72 on Friday. The company has a fifty day moving average of $106.47 and a two-hundred day moving average of $101.80. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -48.46 and a beta of 0.73. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $182.62. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.09 and a current ratio of 2.61.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.06. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The company had revenue of $566.66 million during the quarter, compared to analysts’ expectations of $553.15 million. On average, research analysts expect that ICU Medical will post 3.5 earnings per share for the current year.

Insider Activity

In related news, insider Ben Sousa sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $105.55, for a total transaction of $211,100.00. Following the completion of the sale, the insider now directly owns 1,319 shares in the company, valued at $139,220.45. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other ICU Medical news, Director Elisha W. Finney sold 300 shares of ICU Medical stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $104.95, for a total transaction of $31,485.00. Following the completion of the sale, the director now directly owns 2,129 shares in the company, valued at $223,438.55. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ben Sousa sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $105.55, for a total transaction of $211,100.00. Following the completion of the transaction, the insider now owns 1,319 shares in the company, valued at $139,220.45. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,839 shares of company stock valued at $1,546,014. 6.70% of the stock is currently owned by insiders.

Institutional Trading of ICU Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of ICU Medical by 7.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 168,957 shares of the medical instruments supplier’s stock valued at $20,108,000 after buying an additional 11,364 shares during the period. UBS Group AG grew its holdings in shares of ICU Medical by 241.6% in the third quarter. UBS Group AG now owns 18,864 shares of the medical instruments supplier’s stock valued at $2,245,000 after purchasing an additional 13,341 shares in the last quarter. Citigroup Inc. increased its stake in ICU Medical by 361.4% during the 3rd quarter. Citigroup Inc. now owns 6,173 shares of the medical instruments supplier’s stock worth $735,000 after buying an additional 4,835 shares during the period. FMR LLC lifted its holdings in ICU Medical by 89.9% during the 3rd quarter. FMR LLC now owns 1,124,995 shares of the medical instruments supplier’s stock worth $133,886,000 after buying an additional 532,483 shares in the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in ICU Medical in the 3rd quarter valued at approximately $383,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.